Just out: Mayo Additive Staging System for multiple myeloma: MASS
Uses 5 variables: high risk IgG translocation, 1q gain, del 17, ISS III, & LDH. @BloodCancerJnl
@MayoMyeloma @myelomaMD @MoritzBinderMD @Rfonsi1 @MorieGertz @MayoCancerCare @MayoClinic nature.com/articles/s4140…
Uses 5 variables: high risk IgG translocation, 1q gain, del 17, ISS III, & LDH. @BloodCancerJnl
@MayoMyeloma @myelomaMD @MoritzBinderMD @Rfonsi1 @MorieGertz @MayoCancerCare @MayoClinic nature.com/articles/s4140…
The study used data from 1327 patients to develop the risk stratification model. The model was then validated in 502 patients enrolled in the MMRF CoMMpass study.
Stage migration from RISS and ISS shown below.
Stage migration from RISS and ISS shown below.
There are a lot of risk stratification models. We focus the widest applicability worldwide using markers that are clinically available in most places.
The risk stratification and hazard ratios are valuable for counseling.
The risk stratification and hazard ratios are valuable for counseling.
But in general patients will do better than the numbers shown, because there have been many advancements in the last few years that requires follow up to capture.
Also MASS, ISS, RISS etc indicate prognosis, but approach to therapy needs more granularity.
Also MASS, ISS, RISS etc indicate prognosis, but approach to therapy needs more granularity.
How you overcome the adverse effect of del17 is not the same way you can overcome the poor prognostic effect of ISS III.
Should be IgH translocation not IgG. Sorry about the typo
• • •
Missing some Tweet in this thread? You can try to
force a refresh
